31.28

4.66% -1.53

Parabilis Medicines Inc (PBLS)

Overview News Price History Discussions Forecast

Parabilis Medicines Inc stock is traded at $31.28, with a volume of 349.54K. It is down -4.66% in the last 24 hours and up +14.49% over the past month. Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Previous Close:

$32.81

Open:

$32.53

24h Volume:

349.54K

Relative Volume:

1.02

Market Cap:

$3.83B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+5.85%

1M Performance:

+14.49%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$30.31

$33.15

1-Week Range:

$26.42

$33.15

52-Week Range:

$24.51

$34.47

Parabilis Medicines Inc Stock (PBLS) Company Profile

Name

Parabilis Medicines Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

PBLS's Discussions on Twitter

Compare PBLS vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBLS Parabilis Medicines Inc	31.28	3.83B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Parabilis Medicines Inc Stock (PBLS) Latest News

Jul 23, 2026

Scribe secures $129M in a rare gene editing IPO - BioPharma Dive

Jul 23, 2026

Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo

Jul 23, 2026

RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan

Jul 22, 2026

Jul 21, 2026

Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News

Jul 21, 2026

Jul 19, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 19, 2026

Jul 18, 2026

LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo

Jul 18, 2026

Jul 17, 2026

With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter

Jul 17, 2026

Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha

Jul 17, 2026

Jul 14, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat

Jul 14, 2026

Jul 13, 2026

PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co

Jul 13, 2026

Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS) - MarketBeat

Jul 13, 2026

Jul 10, 2026

Teresa Jurgensen Net Worth (2026) - GuruFocus

Jul 10, 2026

Thomas Rodolpho Kotarakos Net Worth (2026) - GuruFocus

Jul 10, 2026

Helen Huei In Ho Net Worth (2026) - GuruFocus

Jul 10, 2026

Soleus Capital Management, L.p. Net Worth (2026) - GuruFocus

Jul 10, 2026

Soleus Pe Gp Iii, Llc Net Worth (2026) - GuruFocus

Jul 10, 2026

Soleus Gp, Llc Net Worth (2026) - GuruFocus

Jul 10, 2026